Joseph Schwartz
Stock Analyst at Leerink Partners
(3.25)
# 1,088
Out of 5,015 analysts
147
Total ratings
33.59%
Success rate
20.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Schwartz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $80 → $88 | $44.93 | +95.86% | 2 | Sep 29, 2025 | |
| QURE uniQure | Maintains: Outperform | $48 → $68 | $61.56 | +10.47% | 2 | Sep 24, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Market Perform | $12 → $15 | $22.11 | -32.16% | 14 | Sep 9, 2025 | |
| KALV KalVista Pharmaceuticals | Maintains: Outperform | $18 → $20 | $11.50 | +73.91% | 6 | Jul 7, 2025 | |
| INSM Insmed | Maintains: Outperform | $100 → $115 | $162.33 | -29.16% | 4 | Jun 10, 2025 | |
| FULC Fulcrum Therapeutics | Upgrades: Outperform | $4 → $12 | $8.99 | +33.48% | 4 | May 23, 2025 | |
| MAZE Maze Therapeutics | Initiates: Outperform | $28 | $27.43 | +2.08% | 1 | Feb 25, 2025 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $20 → $40 | $25.16 | +58.98% | 6 | Oct 11, 2024 | |
| APLT Applied Therapeutics | Maintains: Outperform | $11 → $14 | $0.94 | +1,388.89% | 2 | Sep 19, 2024 | |
| ANTX AN2 Therapeutics | Upgrades: Outperform | n/a | $1.26 | - | 3 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $12 | $5.96 | +101.34% | 6 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $8 | $1.96 | +308.16% | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $675 → $150 | $173.60 | -13.59% | 5 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $1 | $1.68 | -40.48% | 4 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $6 | $6.75 | -11.11% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $48 | $66.23 | -27.53% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $18 | $21.98 | -18.11% | 5 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $33 → $34 | $69.97 | -51.41% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $122 → $130 | $52.32 | +148.47% | 10 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $148 → $163 | $209.55 | -22.21% | 15 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $2.28 | +338.60% | 7 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $33 | $4.72 | +599.89% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $12 | $11.27 | +6.48% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $115 → $108 | $31.45 | +243.40% | 6 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $4 | $1.38 | +189.86% | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $30 | $15.11 | +98.54% | 2 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $50 | $49.77 | +0.46% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $30 | $87.00 | -65.52% | 6 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $8.30 | +68.67% | 12 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $12 | $2.41 | +397.93% | 2 | Sep 26, 2017 |
Crinetics Pharmaceuticals
Sep 29, 2025
Maintains: Outperform
Price Target: $80 → $88
Current: $44.93
Upside: +95.86%
uniQure
Sep 24, 2025
Maintains: Outperform
Price Target: $48 → $68
Current: $61.56
Upside: +10.47%
Sarepta Therapeutics
Sep 9, 2025
Maintains: Market Perform
Price Target: $12 → $15
Current: $22.11
Upside: -32.16%
KalVista Pharmaceuticals
Jul 7, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $11.50
Upside: +73.91%
Insmed
Jun 10, 2025
Maintains: Outperform
Price Target: $100 → $115
Current: $162.33
Upside: -29.16%
Fulcrum Therapeutics
May 23, 2025
Upgrades: Outperform
Price Target: $4 → $12
Current: $8.99
Upside: +33.48%
Maze Therapeutics
Feb 25, 2025
Initiates: Outperform
Price Target: $28
Current: $27.43
Upside: +2.08%
Travere Therapeutics
Oct 11, 2024
Maintains: Outperform
Price Target: $20 → $40
Current: $25.16
Upside: +58.98%
Applied Therapeutics
Sep 19, 2024
Maintains: Outperform
Price Target: $11 → $14
Current: $0.94
Upside: +1,388.89%
AN2 Therapeutics
Jul 3, 2024
Upgrades: Outperform
Price Target: n/a
Current: $1.26
Upside: -
Jun 24, 2024
Upgrades: Outperform
Price Target: $12
Current: $5.96
Upside: +101.34%
Jun 20, 2024
Maintains: Outperform
Price Target: $6 → $8
Current: $1.96
Upside: +308.16%
Mar 14, 2024
Downgrades: Market Perform
Price Target: $675 → $150
Current: $173.60
Upside: -13.59%
Feb 9, 2024
Downgrades: Market Perform
Price Target: $1
Current: $1.68
Upside: -40.48%
Aug 15, 2023
Downgrades: Market Perform
Price Target: $6
Current: $6.75
Upside: -11.11%
Mar 17, 2023
Initiates: Market Perform
Price Target: $48
Current: $66.23
Upside: -27.53%
Feb 3, 2023
Maintains: Outperform
Price Target: $20 → $18
Current: $21.98
Upside: -18.11%
Feb 3, 2023
Maintains: Market Perform
Price Target: $33 → $34
Current: $69.97
Upside: -51.41%
Feb 3, 2023
Maintains: Outperform
Price Target: $122 → $130
Current: $52.32
Upside: +148.47%
Jan 17, 2023
Maintains: Outperform
Price Target: $148 → $163
Current: $209.55
Upside: -22.21%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $2.28
Upside: +338.60%
Nov 10, 2022
Maintains: Outperform
Price Target: $40 → $33
Current: $4.72
Upside: +599.89%
Nov 4, 2022
Maintains: Outperform
Price Target: $17 → $12
Current: $11.27
Upside: +6.48%
Nov 3, 2022
Maintains: Outperform
Price Target: $115 → $108
Current: $31.45
Upside: +243.40%
May 12, 2022
Maintains: Outperform
Price Target: $6 → $4
Current: $1.38
Upside: +189.86%
May 12, 2022
Maintains: Outperform
Price Target: $34 → $30
Current: $15.11
Upside: +98.54%
May 11, 2022
Maintains: Outperform
Price Target: $53 → $50
Current: $49.77
Upside: +0.46%
May 5, 2022
Maintains: Outperform
Price Target: $50 → $30
Current: $87.00
Upside: -65.52%
Feb 24, 2022
Maintains: Outperform
Price Target: $16 → $14
Current: $8.30
Upside: +68.67%
Sep 26, 2017
Maintains: Outperform
Price Target: $10 → $12
Current: $2.41
Upside: +397.93%